(Image source from: Freepik.com)
The esteemed Tata Institute in Mumbai, a leading cancer research and treatment facility in India, has announced a groundbreaking discovery. After a decade of dedicated work, their team of researchers and doctors have successfully developed a revolutionary tablet. This tablet, according to their claims, has the ability to prevent the recurrence of cancer in patients. Furthermore, it is believed that this treatment can also significantly decrease the negative effects of radiation and chemotherapy by half.
Dr. Rajendra Badve, a respected cancer surgeon at Tata Memorial Hospital, shared insights about the research with NDTV. The experiments involved introducing human cancer cells into rats, which then developed tumors. These rats were subsequently subjected to radiation therapy, chemotherapy, and surgery. The results revealed that when cancer cells perish, they disintegrate into small fragments known as Chromatin particles. These particles can travel through the bloodstream and infiltrate healthy cells, ultimately transforming them into cancerous ones. The Tata Memorial Centre (TMC), in their research, unveiled their findings that dying cancer cells release cell-free chromatin particles (cfChPs) that possess the ability to convert healthy cells into cancerous ones.
In order to address this issue, doctors administered pro-oxidant tablets containing resveratrol and copper (referred to as R+Cu) to rats, according to Dr. Badve's statement to NDTV. These tablets produce Oxygen radicals, which effectively eliminate Chromatin Particles. When ingested orally, R+Cu tablets generate Oxygen radicals in the stomach, which are rapidly absorbed into the bloodstream. These radicals then target and destroy cfChPs present in circulation, preventing the spread of cancer cells to other parts of the body, known as Metastases. The researchers also claim that R+Cu tablets can minimize the toxic effects of chemotherapy.
The researchers have dubbed this phenomenon the "Magic of R+Cu". This tablet is expected to reduce the side effects of cancer treatment by approximately 50%, and it has shown a 30% efficacy in preventing cancer recurrence. Furthermore, it may also be effective in treating pancreatic, lung, and oral cancers. The development of this tablet has been a decade-long endeavor by Tata doctors, and it is currently awaiting approval from the Food Safety and Standards Authority of India (FSSAI). The scientists at TIFR have submitted an application to the FSSAI for the approval of this tablet. Once approved, it is anticipated that the tablet will be available in the market by June or July.
